Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

Randomised, parallel-group comparative efficacy trial enrolling nicotine-dependent adults who receive a 13-week cognitive behavioural smoking-cessation programme with either a single high-dose psilocybin session (30 mg/70 kg) on the Target Quit Date or an 8–10 week transdermal nicotine-patch regimen.

Outcomes include repeated biologically verified smoking-status assessments through 8 weeks post-quit and follow-ups at ~3, 6 and 12 months; a subset (n=50) undergo MRI pre- and post-target quit date to probe neural mechanisms.